Halmos, Balazs <br/><br/>
Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo).  [electronic resource] 

 -  Lung cancer (Amsterdam, Netherlands)  01 2019 
 - 103-111 p.  digital 
<br/><br/> Publication Type: Journal Article; Observational Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1872-8332 
<br/><br/><label>Standard No.: </label>10.1016/j.lungcan.2018.10.028  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Afatinib--therapeutic use<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Drug Dosage Calculations<br/>ErbB Receptors--antagonists & inhibitors<br/>Female<br/>Humans<br/>International Cooperation<br/>Lung Neoplasms<br/>Male<br/>Middle Aged<br/>Mutation--genetics<br/>Protein Kinase Inhibitors--therapeutic use<br/>Survival Analysis<br/>Treatment Outcome